11 Oct APOLLOE4 Alzheon Clinical Study
About this study:
The APOLLOE4 Study is testing an investigational drug to find out whether it may slow the progression of Alzheimer’s disease. At this time there are no approved drugs that halt or arrest the clinical decline typical of Alzheimer’s disease.
The study drug is an oral tablet that is taken twice daily with food. It has been well tolerated in earlier studies and may be a convenient option for Alzheimer’s patients.
You may be able to join the study if you are:
- Experiencing memory loss due to Alzheimer’s disease
- Between 50 and 80 years of age
- Positive for the APOE4/4 gene (genetic testing provided at no cost)
- Accompanied by a caregiver or study partner willing to attend study visits and participate with you
If you qualify, you may receive at no cost:
- Access to the study drug for 18 months that is designed to slow Alzheimer’s disease progression
- Close care and monitoring from an Alzheimer’s disease specialist
- The opportunity to help advance the treatment of Alzheimer’s disease
- Reimbursement for study-related time and travel expenses
What are my costs to take part in this trial?
All tests and procedures that are part of the study and the study visits are provided at no charge to you or your insurance company.
How to get started:
Step 1: Contact our study coordinator, and he/she will give you information and help determine if you qualify.
Step 2: Give Informed Consent. A study doctor will explain the procedures and possible benefits and risks. The study doctor will also answer any questions you may have about the APOLLOE4 Alzheon Clinical Study. To join our study, you must read and sign an Informed Consent document to show that you understand the study and what is required of you.
Step 3: Find out if you are eligible. The study staff will ask some health questions and may do a medical evaluation to see if you meet the requirements.